Which of the following medications acts by inhibiting vascular endothelial growth factor (VEGF)?

INI-CET EXAM -2025

Pharmacology

Easy

Appeared in: INI-CET EXAM -2025

Explanation

Ranibizumab is a monoclonal antibody fragment specifically designed to target and inhibit Vascular Endothelial Growth Factor A (VEGF-A).
VEGF-A is a protein that stimulates angiogenesis, the formation of new blood vessels.
By binding to VEGF-A, Ranibizumab prevents it from interacting with its receptors on endothelial cells.
This inhibition of angiogenesis is therapeutic in conditions characterized by abnormal blood vessel growth, such as neovascular (wet) age-related macular degeneration and diabetic macular edema.

Option B: Pembrolizumab is an immune checkpoint inhibitor, not a VEGF inhibitor. It targets the Programmed Death 1 (PD-1) receptor on T-cells.
Option C: Ipilimumab is an immune checkpoint inhibitor that targets Cytotoxic T-Lymphocyte-Associated protein 4 (CTLA-4), not VEGF.
Option D: Dostarlimab is also an immune checkpoint inhibitor that targets the PD-1 receptor, similar to Pembrolizumab.

Visual 1: Diagram: A visual showing the Ranibizumab antibody fragment binding to a VEGF-A molecule, preventing it from docking with its receptor on an endothelial cell. This illustrates the mechanism of anti-angiogenesis.
Visual 2: Flowchart: A chart comparing the mechanism of action of Anti-VEGF agents versus Immune Checkpoint Inhibitors (PD-1 and CTLA-4 blockers), highlighting their different cellular targets and effects on tumor growth.

Clinical Relevance

Nursing practice connection: This is primarily an exam-oriented knowledge point with limited direct bedside application, so retain Mechanism of Action of Monoclonal Antibodies as background academic context rather than a clinical decision trigger.
Understanding the distinct mechanisms of monoclonal antibodies is vital for nurses to anticipate potential side effects and provide accurate patient education. For example, anti-VEGF agents carry risks of bleeding and hypertension, while immune checkpoint inhibitors can cause a wide range of immune-related adverse events.
A nurse administering Ranibizumab via intravitreal injection must be skilled in ophthalmic procedures and patient monitoring for complications like endophthalmitis and increased intraocular pressure.
What if the patient had metastatic melanoma instead of macular degeneration? The treatment would likely shift from a local anti-VEGF agent (Ranibizumab) to systemic immune checkpoint inhibitors like Pembrolizumab or Ipilimumab to activate a body-wide immune response against the cancer.

How to Approach the Question

First, identify the core of the question, which is to find the drug that inhibits 'vascular endothelial growth factor (VEGF)'.
Scan the options. The names ending in '-mab' indicate they are all monoclonal antibodies.
Recall or look up the specific target of each monoclonal antibody. Differentiate between drugs targeting growth factors (like VEGF) and those targeting immune system components (like PD-1 or CTLA-4).
Ranibizumab is known for its use in eye conditions caused by abnormal blood vessel growth, directly linking it to VEGF.
Pembrolizumab, Ipilimumab, and Dostarlimab are well-known immunotherapy drugs (immune checkpoint inhibitors) used in oncology.
Based on this differentiation, conclude that Ranibizumab is the correct answer as it is the only VEGF inhibitor in the list.

Concept Tested & Keywords

Concept Tested: Mechanism of Action of Monoclonal Antibodies
Stem keywords: medications, inhibiting, vascular endothelial growth factor, VEGF
Lead-in keywords: Which
Negative lead-in flag: false

Q7Hu1RLIypqmWFpbAHCFxh